A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

CompletedOBSERVATIONAL
Enrollment

579

Participants

Timeline

Start Date

November 3, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Non Small Cell Lung Cancer
Trial Locations (19)

0

Burjeel Medical City /ID# 259407, Abu Dhabi

100

National Taiwan University Hospital /ID# 261542, Taipei City

1199

Hospital Italiano de Buenos Aires /ID# 256999, Ciudad Autonoma Buenos Aires

1426

Instituto Alexander Fleming /ID# 256295, Ciudad Autonoma de Buenos Aire

4031

Universitätsspital Basel /ID# 256677, Basel Town

8006

University Hospital Zurich /ID# 256678, Zurich

610041

West China Hospital, Sichuan University /ID# 256906, Chengdu

3109601

Rambam Health Care Campus /ID# 256546, Haifa

90020-090

Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 256487, Porto Alegre

01323-020

Hospital Alemao Oswaldo Cruz /ID# 256486, São Paulo

B3H 1V8

Nova Scotia Health Authority /ID# 256950, Halifax

G1V 4G5

Institut universitaire de cardiologie et de pneumologie de Québec - Université L /ID# 257872, Québec

S7N 0W8

Royal University Hospital /ID# 261272, Saskatoon

589-8511

Kindai University Hospital /ID# 257890, Osakasayama-shi

104-0045

National Cancer Center Hospital /ID# 257889, Chuo-ku

07345

The Catholic University of Korea, Yeouido ST. Mary's Hospital /ID# 261511, Seoul

08017

UOMi Cancer Center - Clinica Tres Torres /ID# 261212, Barcelona

BT9 7AE

Queen's University Belfast /ID# 258458, Belfast

B15 2TH

University Hospitals Birmingham NHS Foundation Trust /ID# 260991, Birmingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY